Obiettivo dello studio:  This phase II trial investigates the efficacy and safety of dabrafenib and trametinib treatment in patients with Erdheim Chester disease that have BRAF V600 gene mutations.
Sponsor:  National Cancer Institute (NCI)
Informazioni di contatto per la fase di prova:  Study Coordinator: Ms. Abha Adat, aadat@mdanderson.org, or the Principal Investigator Filip Janku, 713-563-1930, FJanku@mdanderson.org.
Coinvolgimento richiesto del paziente:  ECD patients with BRAF V600 mutation who have not previously been treated with a BRAF- or MEK-inhibitor and are 18-years or older.
Centri noti che accettano pazienti affetti da ECD nell’ambito dello studio:  MD Anderson, Houston, Texas
Identificativo su ClinicalTrials.gov:  NCT03794297